Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given a consensus rating of “Moderate Buy” by the five research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $21.75.

A number of equities research analysts recently issued reports on CLBT shares. Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th.

Insider Transactions at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 13,269 shares of company stock valued at $169,592 in the last three months. Corporate insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently bought and sold shares of the business. CWM LLC boosted its holdings in Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its holdings in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the period. Advisory Services Network LLC bought a new stake in Cellebrite DI during the third quarter valued at about $40,000. First Horizon Corp boosted its holdings in Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the period. Finally, Vestcor Inc bought a new stake in Cellebrite DI during the third quarter valued at about $70,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Trading Down 2.2%

NASDAQ CLBT opened at $12.89 on Friday. Cellebrite DI has a 1-year low of $11.02 and a 1-year high of $19.98. The company has a market capitalization of $3.22 billion, a PE ratio of 46.04, a price-to-earnings-growth ratio of 1.58 and a beta of 1.15. The firm’s fifty day simple moving average is $13.33 and its 200-day simple moving average is $15.33.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.